TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Homeostatic model assessment (HOMA) index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fibrosis quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: consumption of remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer motor function assessment for upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brunnstrom stage of recovery for hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of in-hospital rate of BARC 3 or 5
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Induction success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retinal emboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Time to reach 95% of peak NTproCNP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Inactivated EV 71 Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Inactivated EV 71 Vaccine
Endpoint domain: Physiological/clinical
Primary endpoint: rate of spontaneous regression of CIN2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: P:F ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 13CO2 excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lymphocyte Transformation Test measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seven-day point-prevalence abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Elevation in cardiac biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mRS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rates of problem behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Teacher-student interactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratings of climate in classrooms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in wrinkle depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intraobserver variability of Transnasal Esophagoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interdisciplinary variability of Transnasal Esophagoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in area or closure of wounds/fissures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Performance on a facial emotion recognition task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of ovarian adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Brain MRI scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change scores of Fugl-Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change scores of Movement Imagery Questionnaire-Revised, Second Edition
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Observed Sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hepcidemia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Frequency of Moderate/Severe Vasomotor Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade of Neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Orthotropia in primary position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of Participants Who Died of Immune Reconstitution Inflammatory Syndrome Associated to Kaposi Sarcoma (IRIS-KS)
Endpoint domain: Mortality/survival
Primary endpoint: FIT Completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high-sensitivity troponin T concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CK-MB concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage Change in Abdominal Visceral Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety as measured by (S)AE occurrences
Endpoint domain: Adverse events/effects
Primary endpoint: Successful infection (development of detectable persistent parasitaemia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Body Dissatisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Resolution of Injected Wart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Spontaneous Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Score on the Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recurrence of basal cell carcinoma (BCC)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Achieving ppPASI75 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in T cell subtypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cobb angle measurement of the patient's coronal deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification and timing of all adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Operative Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Early Postoperative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Time to achieve viral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence with Home Blood Pressure Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Change in Nasal Congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static Stiffness Index (SSI) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic intracranial hemorrhage (sICH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the plasma concentration-time curve during a dose interval (AUCt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scores on the Vigil subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in scores on the Cerberus subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in scores on the Sustained Attention to Response Task (SART) subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Odds ratio for severe fetal/early onset neonatal infection
Endpoint domain: Adverse events/effects
Primary endpoint: Level of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of pain measured by the EVENDOL score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of pain measured by the Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CCO redox state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of safety
Endpoint domain: Adverse events/effects
Primary endpoint: range of motion of the wrist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of volume (arm and hand together)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in prevalence of geriatric syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Subjective ratings using the BORG scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distress at baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression at baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stress at baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Developmental test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area Under the Plasma Concentration-time Curve Over 6 Hours (AUC6) for Acetaminophen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve Over 18 Hours (AUC18) for Acetaminophen After First Morphine Co-administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Acetaminophen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration (Tmax) of Acetaminophen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carboxyhemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term freedom from transplant immunosuppressive drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients affected by minor complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients affected by major complications
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement between the assessment of events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma TFV AUC0-INF GMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBMC TFV-DP AUC GMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mutation rates of HRAS and PIK3CA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in inflammatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: functional deterioration
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Trough Forced Expiratory Volume at 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in hepatic triglyceride content (HTGC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Upregulation of Frataxin (FXN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participants With Treatment-Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline to Endpoint in the Young Mania Rating Scale (YMRS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline to Endpoint in the Hamilton Anxiety Scale (HAM-A) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: successful extubation
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rate of Gastric Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in intensity of pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: degree of awareness about systemic diseases
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of oxygen levels at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stoma closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Death or major disability at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Composite event: vascular death, myocardial infarction, or stroke during the first 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Change of Clinical Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events and/or Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with average day-time ambulatory blood pressure <135/85 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: efficacy failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death of Any Non-accidental Cause or Major Disabling Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Complete Aneurysm Occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative complete remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: painDETECT questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semmes-Weinstein monofilament test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall sedatives daily doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C reactive protein, neutrophil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified borg scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of treatment for infant jaundice
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Length of hospital duration for infant jaundice
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Onset Latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change of muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number and proportion of subjects reporting unsolicited AEs and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number and proportion of subjects with abnormal vital signs/ECG assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mesangial expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional quality of pharyngeal propulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoporosis incidence after chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of participants with successfully developed vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Number of Drinks per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade of clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on bleeding on probing on implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of sleep EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Optic nerve sheath diameter (ONSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Imaging signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha-fetoprotein (AFP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glypican-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA response rate at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depression assessment score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in post-traumatic stress disorder (PTSD) assessment score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in anxiety assessment score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of patients maintaining Hb concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in central and peripheral inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cognitive Disability as Assessed by the Brief International Cognitive Assessment for MS (BICAMS) - Symbol Digit Modalities Test (SDMT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Disability as Assessed by the Brief International Cognitive Assessment for MS (BICAMS) - California Verbal Learning Test - II (CVLT-II)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Disability as Assessed by the Brief International Cognitive Assessment for MS (BICAMS) - Brief Visuospatial Memory Test (BVMT) - Revised
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mortality for ICU
Endpoint domain: Mortality/survival
Primary endpoint: short-term antiviral activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caspofungin Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Arrhythmia Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Signal Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DAS28 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hemoglobin Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Subjects With Anti-H1 Stalk Enzyme-linked Immunosorbent Assay (ELISA) Antibody Concentration Equal or Above the Cut-off of 66 EU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Geometric Increase (MGI) for Anti-H1 Stalk ELISA Antibody Post-vaccination Concentration Compared to Pre-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With a ≥4-fold Rise for Anti-H1 Stalk ELISA Antibody Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time-to-first Remission of Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Patients With Investigator-defined Hypoglycaemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Patients With Significant Adverse Events Based on Standardised MedDRA Query (SMQ)
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of miRNAs as biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pulmonary hypertension prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary hypertension incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke survivor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke survivor and caregiver quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stroke survivor and caregiver stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in mean proliferation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CD8+ TILs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Screen time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Allergic sensitisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Food allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Count of Delirium Diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Luteinizing hormone (LH) pulse frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Spermatozoa concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: child behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: child social skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning